Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01145417 · ClinicalTrials.gov registry record · Phase 3
Pregabalin Trial In HIV Neuropathic Pain
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- Phase 3
- Development phase
- 217
- Enrollment target
NCT01145417 is a Phase 3 study that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 217 participants.
The verdict
NCT01145417, a Phase 3 study, was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 217 participants
- Enrollment target
Study Summary
This study examines the safety of pregabalin over a 6 month period in patients with neuropathic pain associated with HIV infection as an extension of another trial that tests the efficacy of pregabalin.
Interventions
- DRUG pregabalin (Lyrica)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01145417
The ClinicalTrials.gov registry entry for NCT01145417 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pregabalin (Lyrica) is the first listed.
NCT01145417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01145417 about?
NCT01145417 is a clinical study titled "Pregabalin Trial In HIV Neuropathic Pain". This study examines the safety of pregabalin over a 6 month period in patients with neuropathic pain associated with HIV infection as an extension of another trial that tests the efficacy of pregabalin.
What is the current status of trial NCT01145417?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 217 participants. The study started on 2010-07. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01145417?
The interventions under investigation include: pregabalin (Lyrica) (DRUG).
Who is sponsoring clinical trial NCT01145417?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.